Printer Friendly

James Mulry Appointed Director of Marketing, Hematology.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ:CLDA), announced today the appointment of James Mulry as Director of Marketing, Hematology. Mr. Mulry will manage the introduction and support in the United States and Canada of the unique line of hematology analyzers and reagents under Clinical Data's previously announced exclusive distribution arrangements with Melet Schloesing Laboratories of Cergy-Pontoise, France, the developer of the analyzers. Mr. Mulry will report to Clinical Data's Senior Vice President and Chief Operating Officer, Garth Gardner. FDA clearance of the analyzers is anticipated in the current quarter, with product launch expected to occur shortly after clearance.

Prior to joining Clinical Data, Mr. Mulry held the position of Vice President of Sales and Marketing at ABX Diagnostics, a manufacturer of hematology and diagnostic laboratory instruments and reagents. Before joining ABX Diagnostics, Mr. Mulry held positions of increasing scope and responsibility in the Hematology Division of Abbott Diagnostics, a division of Abbott Laboratories.

Dr. Stein, President and CEO of Clinical Data, commented, "We are pleased to add a sales and marketing executive with Jim's knowledge and expertise to our management team. Jim brings over twenty years of management experience with leading hematology diagnostics companies to this newly created position, which we believe will be valuable as we launch our new line of hematology analyzers and reagents throughout North America."

Clinical Data, Inc., through its domestic and foreign subsidiaries, focuses on the needs of physician's offices and smaller clinical laboratories. The Company provides a complete range of products and consulting services to the growing physician's office laboratory market and offers blood chemistry instrumentation and diagnostic assays to clinics and small hospitals throughout the world.

Except for any historical information contained in this press release, the matters discussed herein constitute forward looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties. Actual results could differ materially from those expressed in such statements. For additional important information about Clinical Data readers are referred to the Company's SEC reports and filings, including the Company's Annual Report on Form 10-KSB for the year ended March 31, 2004, filed with the SEC on June 28, 2004, and the Company's Quarterly Reports on Form 10-QSB for quarters ended June 30, 2004, September 30, 2004, and December 31, 2004, filed with the SEC on August 12, 2004, November 12, 2004, and February 11, 2005, respectively.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 15, 2005
Words:404
Previous Article:The New York Stock Exchange and Informed Investors to host a Virtual Investor Forum: Invest in China and Hong Kong on Tuesday, April 19, 2005,...
Next Article:Greater Bay Bancorp Completes Private Offering of $150 Million of Senior Notes.
Topics:


Related Articles
Career.
DuPont.
OBITUARIES.
Who's new: among state insurance regulators.
Sysmex, Bio-Rad Laboratories to Jointly Offer Hematology Solution in US.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters